Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
Stocktwits on MSN3d
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
Biodexa stock soars 76% on FDA Fast Track status for eRapa
Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...
Monthly Prescribing Reference2d
Encapsulated Rapamycin Fast Tracked for Familial Adenomatous Polyposis
The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Biodexa Pharmaceuticals ADRs Rise After Cancer Drug Gets FDA Fast-Track Designation
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
Nasdaq3d
Biodexa Pharmaceuticals Receives FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Treatment
Biodexa Pharmaceuticals has announced that the US FDA has granted Fast Track designation for its drug eRapa, an encapsulated form of rapamycin, which is being developed for familial adenomatous ...
Nasdaq3d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
announced today that the US Food and Drug Administration (“FDA”) has granted Fast Track designation for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of ...
Business Insider4d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical ...
WOOD-TV3d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa has received US FDA Orphan Drug designation for eRapa in FAP and plans to seek a similar designation in Europe. Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage ...